Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals

2008 ◽  
Vol 265 (2) ◽  
pp. 307-317 ◽  
Author(s):  
Jian-quan Zhu ◽  
Wen-zhao Zhong ◽  
Guo-chun Zhang ◽  
Rong Li ◽  
Xu-chao Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Differential Inhibition ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Exon 19

scholarly journals The different clinical significance of EGFR mutations in exon 19 and 21 in non-small cell lung cancer patients of China

Neoplasma ◽  
2011 ◽  
Vol 58 (1) ◽  
pp. 74-81 ◽  
Author(s):  
M. LI ◽  
Q. ZHANG ◽  
L. LIU ◽  
Z. LIU ◽  
Z. ZHOU ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Clinical Significance ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Egfr Mutations ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Exon 19

Pembrolizumab in the non-small-cell lung cancer patients – reasons to consider its use

Oncoreview ◽  
2017 ◽  
Vol 7 (4) ◽  
pp. 199-202
Author(s):  
Magdalena Knetki-Wróblewska
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients

Comparative Proteomics and Bioinformatics Analysis of Tissue from Non-Small Cell Lung Cancer Patients

2017 ◽  
Vol 14 (1) ◽  
pp. 58-77
Author(s):  
Sevgi Gezici ◽  
Mehmet Ozaslan ◽  
Gurler Akpinar ◽  
Murat Kasap ◽  
Maruf Sanli ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Bioinformatics Analysis ◽  
Comparative Proteomics ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document